Kyowa Kirin Pharmaceutical Development Ltd
13
1
2
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
23.1%
3 terminated/withdrawn out of 13 trials
72.7%
-13.8% vs industry average
8%
1 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age
Role: lead
Registry for Patients With X-Linked Hypophosphatemia
Role: lead
Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER)
Role: lead
A Study to Describe the Lived Experience of XLH for Adolescents at End of Skeletal Growth
Role: lead
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years
Role: lead
Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years
Role: lead
A UK Multicentre, Health-Related Quality of Life Study for Children and Adolescents With XLH
Role: lead
Naloxegol Health Outcome Post Authorisation Safety Study
Role: lead
Naloxegol Drug Utilization Post Authorisation Safety Study
Role: lead
Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.
Role: lead
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years
Role: lead
Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients
Role: lead
Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH
Role: lead
All 13 trials loaded